CLDI
HEALTHCARECalidi Biotherapeutics Inc
$0.22+0.01 (+3.77%)PRE
Live · AMEX · May 9, Close
AI Insight
What's Moving CLDI Today?
No stock-specific AI insight has been generated for CLDI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.19$13.20
$0.22
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-5.95
Dividend Yield—
Dividend / Share—
ROE-7.0%
Profit Margin—
Debt / Equity—
Trading
Volume960K
Avg Volume (10D)—
Shares Outstanding15.2M
CLDI News
20 articles- Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AIYahoo Finance·Apr 29, 2026
- RedChip's Biotech Virtual Investor Conference Replays Now AvailableYahoo Finance·Apr 21, 2026
- Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026Yahoo Finance·Apr 21, 2026
- Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026Yahoo Finance·Apr 20, 2026
- Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare PlatformsYahoo Finance·Apr 15, 2026
- Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic TherapyYahoo Finance·Apr 14, 2026
- RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare PlatformsYahoo Finance·Apr 7, 2026
- Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic TherapyYahoo Finance·Apr 7, 2026
- Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026Yahoo Finance·Apr 2, 2026
- Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026Yahoo Finance·Apr 1, 2026
- Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational HighlightsYahoo Finance·Mar 27, 2026
- Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical TrialsYahoo Finance·Mar 24, 2026
- Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to ManufacturingYahoo Finance·Mar 12, 2026
- Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment OptionYahoo Finance·Mar 10, 2026
- Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public OfferingYahoo Finance·Mar 6, 2026
- Calidi Biotherapeutics Announces Proposed Public OfferingYahoo Finance·Mar 5, 2026
- Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO ConferenceYahoo Finance·Feb 20, 2026
- Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO ConferenceYahoo Finance·Feb 12, 2026
- Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026Yahoo Finance·Jan 28, 2026
- Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Dec 5, 2025
All 20 articles loaded
Price Data
Open$0.21
Previous Close$0.21
Day High$0.22
Day Low$0.21
52 Week High$13.20
52 Week Low$0.19
52-Week Range
$0.19$13.20
$0.22
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-5.95
Dividend Yield—
Dividend / Share—
ROE-7.0%
Profit Margin—
Debt / Equity—
Trading
Volume960K
Avg Volume (10D)—
Shares Outstanding15.2M
About Calidi Biotherapeutics Inc
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—